Expert Consensus Recommendations on a Biosimilars Value Framework for the Gulf Cooperation Council Countries
Therapeutic Innovation & Regulatory Science · 2025
DOI: 10.1007/s43441-024-00716-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2025. Verfasst von Khalid A Alnaqbi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Division, Sheikh Tahnoon Medical City and Tawam Hospital, Al Ain, UAE. kalnaqbi@gmail.com. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
This paper aims to develop a biosimilar value framework with local stakeholders in Gulf Cooperation Council (GCC) countries.
Methods
A convenience sample of ten key opinion leaders from the United Arab Emirates, Kingdom of Saudi Arabia, Kuwait, Oman and Qatar participated in an expert panel meeting in November 2022 that examined factors positively influencing biosimilar adoption in these countries. The discussion was structured around a conceptual biosimilar value framework and an overview of biosimilar policies as derived from a targeted review of the peer-reviewed and grey literature.
Results
The expert panel agreed on a biosimilar value framework for the GCC countries that is founded on trust, cost savings and contextual considerations. They emphasized the importance of launching educational initiatives that build trust in and expand knowledge of all stakeholders about biosimilars. This also includes making stakeholders aware of the various value propositions of biosimilars as an instrument to produce, for example, cost savings. Finally, they stressed that biosimilar adoption is influenced by contextual factors such as incentives and implementation efforts.
Conclusion
Our proposed biosimilars value framekwork is the first set of recommendations in the Arab countries designed to help policymakers and decision-makers promote biosimilar adoption, both in high-income GCC countries and in low- and middle-income countries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rheumatology Division, Sheikh Tahnoon Medical City and Tawam Hospital, Al Ain, UAE. kalnaqbi@gmail.com.
- Internal Medicine Department, College of Medicine and Health Sciences, UAE University, Al Ain, UAE. kalnaqbi@gmail.com.
- Emirates Medical Association, Dubai, UAE. kalnaqbi@gmail.com.
- Deputyship of Therapeutic Affairs, Ministry of Health, Riyadh, KSA, Saudi Arabia.
- Colleges of Medicine and Pharmacy, Alfaisal University, Riyadh, KSA, Saudi Arabia.
- Department of Health Economics, Dubai Health Authority, Dubai, UAE.
Zitieren
APA
Alnaqbi, K. A., Al-Jedai, A., Farghaly, M., Omair, M. A., Hamad, A., Abutiban, F. M. A., Shirawi, A. A., Rayes, H. A., Aldallal, S., Fahmy, S., & Simoens, S. (2025). Expert Consensus Recommendations on a Biosimilars Value Framework for the Gulf Cooperation Council Countries. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-024-00716-4
Vancouver
Alnaqbi KA, Al-Jedai A, Farghaly M, Omair MA, Hamad A, Abutiban FMA, et al. Expert Consensus Recommendations on a Biosimilars Value Framework for the Gulf Cooperation Council Countries. Therapeutic Innovation & Regulatory Science. 2025. doi:10.1007/s43441-024-00716-4
BibTeX
@article{Alnaqbi2025,
author = {Alnaqbi, Khalid A and Al-Jedai, Ahmed and Farghaly, Mohamed and Omair, Mohammed A and Hamad, Anas and Abutiban, Fatemah M A and Shirawi, Ali Al and Rayes, Hanan Al and Aldallal, Sarah and Fahmy, Sahar and Simoens, Steven},
title = {Expert Consensus Recommendations on a Biosimilars Value Framework for the Gulf Cooperation Council Countries},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2025},
doi = {10.1007/s43441-024-00716-4}
}
EUVIMED